Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Corporate Presentation

Updated as of June 11, 2018

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.

Research

At Oasmia, we’re developing the next generation of drugs with focus on oncology.

Production

At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share

News

Notification from Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB hereby issues a notification that the Company intends to repay its loan to Nexttobe no later than September 30, 2018 according to previously communicated terms for replacement...
Read more

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia”) on the 29 November 2017 issued a convertible loan with a total nominal amount of MSEK 28. In total MSEK 9 of the convertible loan have during July, at th...
Read more

Status of the Market Authorisation Application of Apealea in the European Union

Oasmia Pharmaceutical AB hereby issues a notification that contrary to what was anticipated in the draft agenda for this month’s meeting by the Committee for Medicinal Products for Human Use (CHMP),...
Read more
To news archive